Kymera Therapeutics Ownership | Who Owns Kymera Therapeutics?
Kymera Therapeutics Ownership Summary
Kymera Therapeutics is owned by 27.69% institutional investors, 2.70% insiders, and 69.62% retail investors. Price t rowe associates inc /md/ is the largest institutional shareholder, holding 9.03% of KYMR shares. Vanguard Health Care Inv is the top mutual fund, with 4.63% of its assets in Kymera Therapeutics shares.
KYMR Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Kymera Therapeutics | 27.69% | 2.70% | 69.62% |
| Sector | Healthcare Stocks | 279.15% | 10.63% | -189.78% |
| Industry | Biotech Stocks | 63.94% | 10.67% | 25.38% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Price t rowe associates inc /md/ | 6.87M | 9.03% | $276.39M |
| Avoro capital advisors | 6.46M | 8.06% | $176.81M |
| Baker bros. advisors lp | 6.00M | 7.48% | $164.11M |
| Wellington management group llp | 5.31M | 6.97% | $213.51M |
| Bvf inc/il | 5.16M | 6.44% | $141.28M |
| Atlas venture life science advisors | 4.90M | 6.43% | $196.98M |
| Vanguard group | 4.89M | 6.42% | $196.62M |
| Fmr | 4.83M | 6.35% | $194.33M |
| Blackrock | 4.16M | 5.87% | $124.04M |
| Blackrock funding, inc. /de | 4.36M | 5.72% | $175.25M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Atlas venture life science advisors | 4.90M | 24.03% | $196.98M |
| Merck | 772.16K | 12.04% | $31.06M |
| Aquilo capital management | 138.52K | 6.80% | $3.79M |
| Bvf inc/il | 5.16M | 5.76% | $141.28M |
| Siren | 2.97M | 5.28% | $119.47M |
| Avoro capital advisors | 6.46M | 2.76% | $176.81M |
| Redmile group | 983.41K | 2.54% | $26.92M |
| Artal group | 3.01M | 2.29% | $89.72M |
| Foresite capital management vi | 146.33K | 2.19% | $4.01M |
| Checkpoint capital | 136.60K | 2.05% | $3.74M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Avoro capital advisors | 6.46M | 2.76% | 1.31M |
| Merck | 772.16K | 12.04% | 772.16K |
| Wellington management group llp | 5.31M | 0.04% | 688.97K |
| Blackrock | 4.16M | 0.00% | 499.77K |
| Millennium management | 510.48K | 0.01% | 394.56K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Deep track capital, lp | - | - | -600.33K |
| Avidity partners management lp | - | - | -500.00K |
| First light asset management | - | - | -383.31K |
| Ecor1 capital | - | - | -350.00K |
| Fmr | 4.83M | 0.01% | -278.72K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Merck | 772.16K | 12.04% | 772.16K | $31.06M |
| Patient square capital lp | 142.20K | 1.61% | 142.20K | $3.89M |
| Norges bank | 91.23K | 0.00% | 91.23K | $3.67M |
| Exoduspoint capital management, lp | 14.13K | 0.00% | 14.13K | $568.00K |
| Peak6 investments | 13.00K | 0.00% | 13.00K | $388.05K |
Sold Out
| Holder | Change |
|---|---|
| Global financial private client | -1.00 |
| Financial gravity asset management | -2.00 |
| Capital performance advisors llp | -3.00 |
| Riggs asset managment | -7.00 |
| Nelson, van denburg & campbell wealth management group | -8.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 20 | -89.07% | 22,191,205 | -69.06% | 27 | 0.31% | 7 | -92.39% | 4 | -93.10% |
| Dec 31, 2024 | 180 | -0.55% | 71,156,642 | 3.18% | 93 | 1.14% | 88 | -4.35% | 59 | -4.84% |
| Sep 30, 2024 | 181 | 16.03% | 68,964,551 | 2.37% | 90 | 1.00% | 93 | 6.90% | 62 | 31.91% |
| Jun 30, 2024 | 155 | -4.32% | 67,367,833 | 0.44% | 95 | 0.72% | 86 | -14.85% | 47 | 11.90% |
| Mar 31, 2024 | 162 | 20.00% | 67,073,034 | 11.04% | 114 | 1.07% | 101 | 48.53% | 42 | -17.65% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Health Care Inv | 3.01M | 4.63% | 662.16K |
| T. Rowe Price New Horizons | 2.90M | 4.14% | 131.16K |
| US Small-Cap Growth II Equity Comp | 2.90M | 4.14% | -150.42K |
| Fidelity Growth Compy Commingled Pl O | 2.24M | 3.46% | 52.60K |
| Fidelity Growth Compy Commingled Pl S | 2.11M | 3.01% | 46.51K |
| Vanguard Total Stock Mkt Idx Inv | 1.79M | 2.74% | 2.16K |
| Vanguard US Total Market Shares ETF | 1.54M | 2.38% | 1.91K |
| Vanguard Small Cap Index | 1.39M | 2.14% | 5.13K |
| Fidelity Growth Company Fund | 1.47M | 2.10% | 38.26K |
| T. Rowe Price Health Sciences | 1.37M | 1.95% | 190.87K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jun 30, 2025 | BVF PARTNERS L P/IL | See Remarks and Footnotes | Buy | $2.59M |
| Jun 30, 2025 | BVF PARTNERS L P/IL | See Remarks and Footnotes | Buy | $5.09M |
| Jun 30, 2025 | BVF PARTNERS L P/IL | See Remarks and Footnotes | Buy | $6.27M |
| Jun 30, 2025 | BAKER BROS. ADVISORS LP | - | Buy | $26.41M |
| Jun 30, 2025 | BAKER BROS. ADVISORS LP | - | Buy | $5.52 |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | 7 | 7 |
| 2025 Q1 | - | 9 |
| 2024 Q4 | - | 1 |
| 2024 Q3 | 5 | 16 |
| 2024 Q2 | - | 9 |
KYMR Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools